Comment NAVIGATOR: physical activity for cardiovascular health?

In The Lancet, Thomas Yates and colleagues report new findings from the NAVIGATOR trial, a multicentre, international, randomised, placebo-controlled trial that examined the effect of nateglinide, valsartan, or both, on cardiovascular events in patients with impaired glucose tolerance and either existing cardiovascular disease or at least one additional risk factor. The results of this cohort analysis of the association between daily ambulatory activity, as assessed by pedometer, and a composite of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke, show a graded and independent inverse association of both baseline levels and change over a year of daily ambulatory activity and subsequent risk of a cardiovascular event—HR per 2000 steps per day 0·90 (95% CI 0·84–0·96) and 0·92 (0·86–0·99), respectively.
Source: LANCET - Category: Journals (General) Authors: Tags: Comment Source Type: research

Related Links:

CONCLUSION: For patients with ULMCA disease and LVSD, there was no significant difference between DES and CABG in terms of efficacy and safety. Treatment with DES was an acceptable alternative to CABG. PMID: 32435839 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
A significant amount of clinical and research interest in thrombosis is focused on large vessels (e.g., stroke, myocardial infarction, deep venous thrombosis, etc.); however, thrombosis is often present in the microcirculation in a variety of significant human diseases, such as disseminated intravascular coagulation, thrombotic microangiopathy, sickle cell disease, and others. Further, microvascular thrombosis has recently been demonstrated in patients with COVID-19, and has been proposed to mediate the pathogenesis of organ injury in this disease.
Source: Translational Research - Category: Research Authors: Tags: Review Article Source Type: research
FRIDAY, May 22, 2020 (American Heart Association News) -- High blood pressure is one of the top risk factors for heart attack and stroke. It's also common among people who develop severe symptoms of COVID-19. So, with more people at home practicing...
Source: - Daily MedNews - Category: General Medicine Source Type: news
Title: AHA News: After Diabetes, Stroke and Heart Attack, She's Learning to'Fight Smart 'Category: Health NewsCreated: 5/21/2020 12:00:00 AMLast Editorial Review: 5/22/2020 12:00:00 AM
Source: MedicineNet Heart General - Category: Cardiology Source Type: news
AbstractThe coronary artery calcium data and reporting system (CAC-DRS) is a novel reporting system based on CAC severity. Lung cancer patients have a high risk of cardiovascular disease (CVD), for which CAC severity may provide additional prognostic information. Using non-gated, non-contrast computed tomography (CT), we evaluated the CAC-DRS for predicting CVD and all-cause death in patients with potentially curable resected lung cancer. We retrospectively studied 309 consecutive patients without a history of CVD (mean age 67.4  ± 8.2 years, 61% male) who underwent curative surgery for non-small-...
Source: Heart and Vessels - Category: Cardiology Source Type: research
THURSDAY, May 21, 2020 (American Heart Association News) -- Hyvelle Ferguson-Davis was reviewing paperwork at her office in Fort Lauderdale, Florida, when the headache started. It grew stronger and stronger and her eyes blurred, making it difficult...
Source: - Daily MedNews - Category: General Medicine Source Type: news
Abstract Peripheral artery disease is a common disorder and a major cause of morbidity and mortality worldwide. Therapy is directed at reducing the risk of major adverse cardiovascular events and at ameliorating symptoms. Medical therapy is effective at reducing the incidence of myocardial infarction and stroke to which these patients are prone but is inadequate in relieving limb-related symptoms, such as intermittent claudication, rest pain, and ischemic ulceration. Limb-related morbidity is best addressed with surgical and endovascular interventions that restore perfusion. Current medical therapies have only mod...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Tags: Arterioscler Thromb Vasc Biol Source Type: research
Abstract Background: Rivaroxaban 2.5mg twice daily plus aspirin 100mg reduced the risk of cardiovascular events as compared to aspirin monotherapy in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome. Methods: The current pre-specified analysis was performed to assess the NCB of adding rivaroxaban 2.5mg twice daily to aspirin monotherapy in patients with chronic vascular disease in the COMPASS study cohor...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Authors: Sawano S, Sakakura K, Yamamoto K, Taniguchi Y, Tsukui T, Seguchi M, Wada H, Momomura SI, Fujita H Abstract Recently, we developed a novel acute myocardial infarction (AMI) risk stratification system (nARS), which stratifies AMI patients into low- (L), intermediate- (I), and high- (H) risk groups. We have shown that the nARS shortened the length of intensive care unit (ICU) stay as well as that of hospitalization. However, the incidence of AMI-related adverse outcomes has not been fully investigated. The purpose of this study was to investigate the incidence of severe complications requiring ICU care among ...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Authors: Wada H, Dohi T, Miyauchi K, Nishio R, Takeuchi M, Takahashi N, Endo H, Ogita M, Iwata H, Kasai T, Okazaki S, Isoda K, Suwa S, Daida H Abstract Although an elevated neutrophil to lymphocyte ratio (NLR) has been associated with the adverse outcomes of coronary artery disease (CAD), less is known about its prognostic value among patients with low high-sensitivity C-reactive protein (hs-CRP) levels. We enrolled 2,591 consecutive patients with stable CAD who underwent elective percutaneous coronary intervention (PCI) and had available data on preprocedural hs-CRP and NLR between 2000 and 2016. Of these patients...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
More News: Cardiology | Cardiovascular | Diovan | General Medicine | Heart | Heart Attack | Stroke